Results 131 to 140 of about 186,128 (186)

Correction: Infographic: 2-year efficacy, durability and safety of intravitreal faricimab with treat-and-extend dosing up to 16 weeks in neovascular age-related macular degeneration (pooled results from TENAYA and LUCERNE). [PDF]

Eye (Lond)
Wijesingha N, Kotecha A, Margaron P, Sivaprasad S.   +3 more
europepmc   +1 more source

INFOGRAPHIC: 2-year efficacy, durability and safety of intravitreal faricimab with treat-and-extend dosing up to 16 weeks in diabetic macular oedema (pooled results from YOSEMITE and RHINE). [PDF]

Eye (Lond)
Wijesingha N, Gibson K, Willis JR, Sivaprasad S.   +3 more
europepmc   +1 more source

Long Intervals between Intravitreal Injections Using a Treat-and-Extend Protocol in a Real-Life Context in AMD: The LIRE Study. [PDF]

Ophthalmologica
Leroux P, Agard E, Billant J, Levron A, Bouvarel H, Badri Y, Douma I, Pradat P, Dot C.   +8 more
europepmc   +1 more source

Impact of treat and extend criteria on proportions that can be extended after loading phase of 2 mg aflibercept therapy for neovascular age related macular degeneration: PRECISE Report 5. [PDF]

Eye (Lond)
Thottarath S, Gurudas S, Chandak S, Patel PJ, Kotagiri A, Pearce I, McKibbin M, Menon G, Burton BJL, Talks J, Grabowska A, Ghanchi F, Gale R, Karatsai E, Chandra S, Sivaprasad S.   +15 more
europepmc   +1 more source

Efficacy and Safety of Intravitreal Aflibercept Using a Treat-and-Extend Regimen For Neovascular Age-Related Macular Degeneration-The Aries Study: A Randomized Clinical Trial-Erratum. [PDF]

Retina, 2022
europepmc   +1 more source

Infographic: 2-year efficacy, durability and safety of intravitreal faricimab with treat-and-extend dosing up to 16 weeks in neovascular age-related macular degeneration (pooled results from TENAYA and LUCERNE). [PDF]

Eye (Lond)
Wijesingha N, Kotecha A, Margaron P, Sivaprasad S.   +3 more
europepmc   +1 more source

Switching to Intravitreal Brolucizumab after Ranibizumab or Aflibercept Using Treat and Extend Regimen for Neovascular Age-Related Macular Degeneration in Japanese Patients: 1-Year Results and Factors Associated with Treatment Responsiveness. [PDF]

J Clin Med
Hirayama K, Yamamoto M, Honda S, Kyo A, Misawa N, Kohno T.   +5 more
europepmc   +1 more source

Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration Beyond One Year of Treatment: AZURE, a Randomized Trial of Treat-and-Extend vs. Fixed Dosing. [PDF]

Adv Ther
Kodjikian L, Arias Barquet L, Papp A, Kertes PJ, Midena E, Ernest J, Silva R, Schmelter T, Niesen T, Leal S.   +9 more
europepmc   +1 more source

Demographics of patients receiving Intravitreal anti-VEGF treatment in real-world practice: healthcare research data versus randomized controlled trials [PDF]

core   +1 more source

Vitrectomy as an Adjunct to Treat-and-Extend Anti-VEGF Injections for Diabetic Macular Edema: The Vitrectomy in Diabetic Macular Oedema (VIDEO) Randomized Clinical Trial.

JAMA Ophthalmol
Maguire MJ, Laidlaw A, Hammond C, Muqit MMK, Steel D, Dinah C, Lee E, Hillier R, Almeida G, Hussain R, Gordon-Bennet P, Hughes E, Alexander P, Vaideanu-Collins D, Jackson T.   +14 more
europepmc   +1 more source